• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
09NovNovember 9, 2025

Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility Data

05NovNovember 5, 2025

SITC 2025

05NovNovember 5, 2025

Preclinical Antitumor Activity of Potent and Orally Bioavailable PROTAC HPK1 Degraders as Monotherapy or Combined With an Anti-PD-1 Antibody

24OctOctober 24, 2025

AACR-NCI-EORTC 2025

22OctOctober 22, 2025

Vepdegestrant, a PROTAC ER Degrader, Induces Greater ER Degradation and Antitumor Activity Relative to SERDs in Preclinical ER+ Breast Cancer Models

22OctOctober 22, 2025

Preclinical Activity of ARV-806, a PROTAC KRAS G12D Degrader

17OctOctober 17, 2025

ESMO 2025

17OctOctober 17, 2025

TACTIVE-N: Phase 2 Study of Neoadjuvant Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, or Anastrozole in Postmenopausal ER+/Human Epidermal Growth Factor Receptor 2-Negative Localized Breast Cancer

17OctOctober 17, 2025

Patient-Reported Outcomes (PROs) with Vepdegestrant (VEP) vs Fulvestrant (FUL) in Patients (pts) with Estrogen Receptor (ER) 1 Gene Mutated (ESR1m) ER+/Human Epidermal Growth Factor Receptor 2 (HER2): Advanced Breast Cancer (aBC) in the Phase 3 VERITAC-2 Trial

07OctOctober 7, 2025

WMS 2025

  Prev123…5Next  
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2026 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE